Literature DB >> 22549056

Anti-vascular endothelial growth factor treatment for eye diseases.

Ning Cheung, Dennis S C Lam, Tien Y Wong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22549056     DOI： 10.1136/bmj.e2970

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  13 in total

1.  FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice.

Authors:  Zhongjie Fu; Yan Gong; Raffael Liegl; Zhongxiao Wang; Chi-Hsiu Liu; Steven S Meng; Samuel B Burnim; Nicholas J Saba; Thomas W Fredrick; Peyton C Morss; Ann Hellstrom; Saswata Talukdar; Lois E H Smith
Journal:  Cell Rep       Date:  2017-02-14       Impact factor: 9.423

2.  Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheep.

Authors:  Tugba Cakmak Argun; Ozlem Yalcin Tok; Levent Tok; Gulsen Yilmaz; Fatma Meric Yilmaz; Alime Gunes; Mehmet Argun; Osman Butuner
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

3.  Bevacizumab versus ranibizumab: why are we not playing the joker?

Authors:  Roberto Banfi; Francesco Attanasio; Nadia Palazzi; Silvia Colombini; Tiziana Falai; Michele Cecchi; Gianni Virgili
Journal:  Int J Clin Pharm       Date:  2013-08

4.  Cytochrome P450 Oxidase 2C Inhibition Adds to ω-3 Long-Chain Polyunsaturated Fatty Acids Protection Against Retinal and Choroidal Neovascularization.

Authors:  Yan Gong; Zhongjie Fu; Matthew L Edin; Chi-Hsiu Liu; Zhongxiao Wang; Zhuo Shao; Thomas W Fredrick; Nicholas J Saba; Peyton C Morss; Samuel B Burnim; Steven S Meng; Fred B Lih; Kin Sing Stephen Lee; Elizabeth P Moran; John Paul SanGiovanni; Ann Hellström; Bruce D Hammock; Darryl C Zeldin; Lois E H Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-14       Impact factor: 8.311

5.  Novel Role of Prereplication Complex Component Cell Division Cycle 6 in Retinal Neovascularization.

Authors:  Raj Kumar; Gadiparthi N Rao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-03-03       Impact factor: 8.311

6.  The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice.

Authors:  Zhi-Chao Dong; Ming-Ming Wu; Yun-Long Zhang; Qiu-Shi Wang; Chen Liang; Xiao Yan; Lei-Xin Zou; Chen Chen; Xiao Han; Bo Zhang; Zhi-Ren Zhang
Journal:  Acta Pharmacol Sin       Date:  2020-12-10       Impact factor: 7.169

Review 7.  ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases.

Authors:  Yan Gong; Zhongjie Fu; Raffael Liegl; Jing Chen; Ann Hellström; Lois Eh Smith
Journal:  Am J Clin Nutr       Date:  2017-05-17       Impact factor: 7.045

8.  Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept.

Authors:  Adam Walker; Chun-Wa Chung; Margarete Neu; Manish Burman; Thil Batuwangala; Gavin Jones; Chi-Man Tang; Michael Steward; Michael Mullin; Nadia Tournier; Alan Lewis; Justyna Korczynska; Vicky Chung; Ian Catchpole
Journal:  J Biol Chem       Date:  2016-01-04       Impact factor: 5.157

9.  Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis.

Authors:  Yan Gong; Zhuo Shao; Zhongjie Fu; Matthew L Edin; Ye Sun; Raffael G Liegl; Zhongxiao Wang; Chi-Hsiu Liu; Samuel B Burnim; Steven S Meng; Fred B Lih; John Paul SanGiovanni; Darryl C Zeldin; Ann Hellström; Lois E H Smith
Journal:  EBioMedicine       Date:  2016-09-30       Impact factor: 8.143

10.  Diffusion of anti-VEGF injections in the Portuguese National Health System.

Authors:  Ana Patrícia Marques; António Filipe Macedo; Julian Perelman; Pedro Aguiar; Amândio Rocha-Sousa; Rui Santana
Journal:  BMJ Open       Date:  2015-11-23       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.